NOVO NORDISK A/S-B (NOV.DE) Fundamental Analysis & Valuation
FRA:NOV • DK0062498333
Current stock price
36.228 EUR
+2.22 (+6.54%)
Last:
This NOV.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. NOV.DE Profitability Analysis
1.1 Basic Checks
- In the past year NOV was profitable.
- In the past year NOV had a positive cash flow from operations.
- In the past 5 years NOV has always been profitable.
- In the past 5 years NOV always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 18.87%, NOV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 52.79%, NOV belongs to the top of the industry, outperforming 93.88% of the companies in the same industry.
- NOV has a Return On Invested Capital of 30.79%. This is amongst the best in the industry. NOV outperforms 95.92% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for NOV is significantly above the industry average of 14.21%.
- The last Return On Invested Capital (30.79%) for NOV is well below the 3 year average (43.61%), which needs to be investigated, but indicates that NOV had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.87% | ||
| ROE | 52.79% | ||
| ROIC | 30.79% |
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
1.3 Margins
- With an excellent Profit Margin value of 33.14%, NOV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- In the last couple of years the Profit Margin of NOV has remained more or less at the same level.
- NOV's Operating Margin of 41.30% is amongst the best of the industry. NOV outperforms 95.92% of its industry peers.
- NOV's Operating Margin has been stable in the last couple of years.
- NOV has a better Gross Margin (80.98%) than 85.71% of its industry peers.
- NOV's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 41.3% | ||
| PM (TTM) | 33.14% | ||
| GM | 80.98% |
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
2. NOV.DE Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NOV is creating value.
- Compared to 1 year ago, NOV has about the same amount of shares outstanding.
- NOV has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, NOV has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 3.23 indicates that NOV is not in any danger for bankruptcy at the moment.
- NOV has a Altman-Z score of 3.23. This is comparable to the rest of the industry: NOV outperforms 53.06% of its industry peers.
- The Debt to FCF ratio of NOV is 4.52, which is a neutral value as it means it would take NOV, 4.52 years of fcf income to pay off all of its debts.
- NOV has a Debt to FCF ratio (4.52) which is in line with its industry peers.
- A Debt/Equity ratio of 0.61 indicates that NOV is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.61, NOV is in line with its industry, outperforming 53.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 4.52 | ||
| Altman-Z | 3.23 |
ROIC/WACC4.92
WACC6.26%
2.3 Liquidity
- A Current Ratio of 0.80 indicates that NOV may have some problems paying its short term obligations.
- With a Current ratio value of 0.80, NOV is not doing good in the industry: 81.63% of the companies in the same industry are doing better.
- A Quick Ratio of 0.57 indicates that NOV may have some problems paying its short term obligations.
- NOV's Quick ratio of 0.57 is on the low side compared to the rest of the industry. NOV is outperformed by 83.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.57 |
3. NOV.DE Growth Analysis
3.1 Past
- NOV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.77%.
- NOV shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.66% yearly.
- NOV shows a small growth in Revenue. In the last year, the Revenue has grown by 6.43%.
- NOV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.48% yearly.
EPS 1Y (TTM)1.77%
EPS 3Y23.52%
EPS 5Y20.66%
EPS Q2Q%-4.73%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-7.63%
3.2 Future
- NOV is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.93% yearly.
- NOV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.35% yearly.
EPS Next Y-7.2%
EPS Next 2Y-3.65%
EPS Next 3Y0.38%
EPS Next 5Y3.93%
Revenue Next Year-6.27%
Revenue Next 2Y-1.41%
Revenue Next 3Y1.06%
Revenue Next 5Y3.35%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. NOV.DE Valuation Analysis
4.1 Price/Earnings Ratio
- NOV is valuated reasonably with a Price/Earnings ratio of 11.76.
- 77.55% of the companies in the same industry are more expensive than NOV, based on the Price/Earnings ratio.
- When comparing the Price/Earnings ratio of NOV to the average of the S&P500 Index (26.54), we can say NOV is valued rather cheaply.
- Based on the Price/Forward Earnings ratio of 12.67, the valuation of NOV can be described as correct.
- Based on the Price/Forward Earnings ratio, NOV is valued a bit cheaper than the industry average as 75.51% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 21.68, NOV is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.76 | ||
| Fwd PE | 12.67 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NOV indicates a rather cheap valuation: NOV is cheaper than 91.84% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, NOV is valued a bit more expensive than 63.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.66 | ||
| EV/EBITDA | 6.45 |
4.3 Compensation for Growth
- NOV has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.57
EPS Next 2Y-3.65%
EPS Next 3Y0.38%
5. NOV.DE Dividend Analysis
5.1 Amount
- With a Yearly Dividend Yield of 4.74%, NOV is a good candidate for dividend investing.
- In the last 3 months the price of NOV has falen by -27.15%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
- Compared to an average industry Dividend Yield of 1.96, NOV pays a better dividend. On top of this NOV pays more dividend than 83.67% of the companies listed in the same industry.
- NOV's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.74% |
5.2 History
- On average, the dividend of NOV grows each year by 19.05%, which is quite nice.
Dividend Growth(5Y)19.05%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
- NOV pays out 50.53% of its income as dividend. This is a bit on the high side, but may be sustainable.
- NOV's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP50.53%
EPS Next 2Y-3.65%
EPS Next 3Y0.38%
NOV.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:NOV (4/30/2026, 5:29:12 PM)
36.228
+2.22 (+6.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)02-03 2026-02-03/amc
Earnings (Next)05-06 2026-05-06
Inst Owners31.87%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap122.82B
Revenue(TTM)309.06B
Net Income(TTM)102.43B
Analysts67.57
Price Target42.87 (18.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.74% |
Yearly Dividend1.56
Dividend Growth(5Y)19.05%
DP50.53%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.82%
Min EPS beat(2)-7.04%
Max EPS beat(2)1.39%
EPS beat(4)2
Avg EPS beat(4)-0.71%
Min EPS beat(4)-7.04%
Max EPS beat(4)3.94%
EPS beat(8)5
Avg EPS beat(8)1.01%
EPS beat(12)8
Avg EPS beat(12)1.47%
EPS beat(16)11
Avg EPS beat(16)1.68%
Revenue beat(2)1
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)1.07%
Revenue beat(4)1
Avg Revenue beat(4)-0.92%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)1.07%
Revenue beat(8)3
Avg Revenue beat(8)0.15%
Revenue beat(12)6
Avg Revenue beat(12)0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.84%
PT rev (1m)-13.2%
PT rev (3m)-19.72%
EPS NQ rev (1m)10.83%
EPS NQ rev (3m)15.44%
EPS NY rev (1m)-3.37%
EPS NY rev (3m)-6.18%
Revenue NQ rev (1m)2.26%
Revenue NQ rev (3m)-37.39%
Revenue NY rev (1m)-1.7%
Revenue NY rev (3m)-6.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.76 | ||
| Fwd PE | 12.67 | ||
| P/S | 2.97 | ||
| P/FCF | 31.66 | ||
| P/OCF | 7.71 | ||
| P/B | 4.73 | ||
| P/tB | 14.34 | ||
| EV/EBITDA | 6.45 |
EPS(TTM)3.08
EY8.5%
EPS(NY)2.86
Fwd EY7.89%
FCF(TTM)1.14
FCFY3.16%
OCF(TTM)4.7
OCFY12.98%
SpS12.2
BVpS7.66
TBVpS2.53
PEG (NY)N/A
PEG (5Y)0.57
Graham Number23.0395 (-36.4%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.87% | ||
| ROE | 52.79% | ||
| ROCE | 39.01% | ||
| ROIC | 30.79% | ||
| ROICexc | 33.56% | ||
| ROICexgc | 59.2% | ||
| OM | 41.3% | ||
| PM (TTM) | 33.14% | ||
| GM | 80.98% | ||
| FCFM | 9.38% |
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
ROICexc(3y)50.94%
ROICexc(5y)53.03%
ROICexgc(3y)100.46%
ROICexgc(5y)105.49%
ROCE(3y)55.75%
ROCE(5y)58.53%
ROICexgc growth 3Y-22.89%
ROICexgc growth 5Y-7.78%
ROICexc growth 3Y-18.13%
ROICexc growth 5Y-11.63%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
F-Score5
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 4.52 | ||
| Debt/EBITDA | 0.79 | ||
| Cap/Depr | 409.94% | ||
| Cap/Sales | 29.16% | ||
| Interest Coverage | 37.34 | ||
| Cash Conversion | 79.59% | ||
| Profit Quality | 28.3% | ||
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 3.23 |
F-Score5
WACC6.26%
ROIC/WACC4.92
Cap/Depr(3y)363.9%
Cap/Depr(5y)282.93%
Cap/Sales(3y)21.19%
Cap/Sales(5y)15.43%
Profit Quality(3y)60.31%
Profit Quality(5y)79.23%
High Growth Momentum
Growth
EPS 1Y (TTM)1.77%
EPS 3Y23.52%
EPS 5Y20.66%
EPS Q2Q%-4.73%
EPS Next Y-7.2%
EPS Next 2Y-3.65%
EPS Next 3Y0.38%
EPS Next 5Y3.93%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-7.63%
Revenue Next Year-6.27%
Revenue Next 2Y-1.41%
Revenue Next 3Y1.06%
Revenue Next 5Y3.35%
EBIT growth 1Y-4.76%
EBIT growth 3Y19.04%
EBIT growth 5Y18.51%
EBIT Next Year8.72%
EBIT Next 3Y6.24%
EBIT Next 5Y8.11%
FCF growth 1Y-58.38%
FCF growth 3Y-23.26%
FCF growth 5Y-0.6%
OCF growth 1Y-1.54%
OCF growth 3Y14.72%
OCF growth 5Y18.05%
NOVO NORDISK A/S-B / NOV.DE Fundamental Analysis FAQ
What is the fundamental rating for NOV stock?
ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE.
Can you provide the valuation status for NOVO NORDISK A/S-B?
ChartMill assigns a valuation rating of 5 / 10 to NOVO NORDISK A/S-B (NOV.DE). This can be considered as Fairly Valued.
How profitable is NOVO NORDISK A/S-B (NOV.DE) stock?
NOVO NORDISK A/S-B (NOV.DE) has a profitability rating of 9 / 10.
What is the financial health of NOVO NORDISK A/S-B (NOV.DE) stock?
The financial health rating of NOVO NORDISK A/S-B (NOV.DE) is 3 / 10.
Can you provide the dividend sustainability for NOV stock?
The dividend rating of NOVO NORDISK A/S-B (NOV.DE) is 7 / 10 and the dividend payout ratio is 50.53%.